Rituximab in Refractory Myasthenia Gravis
| dc.contributor.author | Tajouri, Malak | |
| dc.date.accessioned | 2020-07-07T10:08:06Z | |
| dc.date.available | 2020-07-07T10:08:06Z | |
| dc.date.issued | 2020-02-17 | |
| dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/1722 | |
| dc.description | Myasthenia gravis (MG) from Greek: myos = muscle, asthenos = weakness, and Latin: gravis = severe, is an autoimmune neuromuscular disease primarily mediated by antibodies (Abs) targeting either the nicotinic acetylcholine receptor (AChR), or the components of the postsynaptic membrane at the neuromuscular junction (NMJ) leading to impaired neuromuscular transmission. (1) Standard treatment such as Cholinesterase inhibitors cannot completely relieve the symptoms of MG or prevent the progression of the disease, glucocorticoids are also widely used to treat MG often causing severe adverse effects, and immunosuppressant such as glucocorticosteroids , often used as first-line MG therapies but for long-term use of immunosuppressive agents, often leads to significant side effects | en_US |
| dc.description.abstract | Myasthenia gravis (MG) is an autoimmune disease caused by complement-fixing antibodies against acetylcholine receptors (AChR). Cholinesterase inhibitors, Glucocorticoid , which is currently recommended as a first-line treatment for MG, although it has drawbacks, including possible toxicity and inefficiency in patients with refractory MG and traditional immunosuppressants stay the standard treatments at present, but they have demonstrated limitations and often unsatisfactory efficacy so the target specific therapeutic interventions should therefore be directed against antibodies For example, Rituximab is a monoclonal antibody (mAbs) that could be more active and longer lasting with less serious side effects. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title | Rituximab in Refractory Myasthenia Gravis | en_US |
| dc.type | Other | en_US |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Attribution 3.0 United States